Value of [(18)F]-FDG positron emission tomography in patients with recurrent glioblastoma receiving bevacizumab

BACKGROUND: Treatment of recurrent glioblastoma (GBM) with bevacizumab can induce MRI changes that confound the determination of progression. We sought to determine the value of [(18)F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in GBM patients receiving bevacizumab at the time of s...

Descripción completa

Detalles Bibliográficos
Autores principales: Graham, Maya S, Krebs, Simone, Bale, Tejus, Domfe, Kwaku, Lobaugh, Stephanie M, Zhang, Zhigang, Dunphy, Mark P, Kaley, Thomas, Young, Robert J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236386/
https://www.ncbi.nlm.nih.gov/pubmed/32642703
http://dx.doi.org/10.1093/noajnl/vdaa050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236386/
https://www.ncbi.nlm.nih.gov/pubmed/32642703
http://dx.doi.org/10.1093/noajnl/vdaa050

Ejemplares similares